ストックスクリーナーアプリを入手
14.55
0.00%
0.00
プレマーケット:
15.15
0.60
+4.12%
前日終値:
$14.55
開ける：
$15.87
24時間の取引高:
436.09K
Relative Volume:
66.00
時価総額：
$785.47M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$14.10
$15.87
1週間の範囲:
$14.10
$15.87
52週間の値動き範囲:
$14.10
$15.87
Eikon Therapeutics Inc Stock (EIKN) Company Profile
Compare EIKN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EIKN
Eikon Therapeutics Inc
|
14.55 | 782.77M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.87 | 121.26B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.28 | 83.04B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
828.24 | 50.22B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.00 | 43.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
348.85 | 39.16B | 4.98B | 69.60M | 525.67M | 0.5198 |
Eikon Therapeutics Inc (EIKN) 最新ニュース
Wall Street Braces For IPO Boom: Goldman Says 2026 Listings Could Hit $160 Billion As Tech, AI Lead - Benzinga
Eikon Therapeutics completes IPO and updates governance documents - The Globe and Mail
Eikon, Agomab raise $350M total in IPOs, sink in aftermarket: Public Equity Report - biocentury.com
Finance Watch: Four IPOs In One Week - Citeline News & Insights
Eikon Therapeutics, Late-Stage Clinical Oncology Drug Developer, Files for Nasdaq IPO - TradingView
Eikon Therapeutics valued at $860 million in Nasdaq debut - marketscreener.com
Eikon Therapeutics Continues the IPO Parade, Raising $381M for Cancer Drug Clinical Trials - MedCity News
Covington, Davis Polk Lead Eikon's Upsized $381M IPO - Law360
Eikon Therapeutics Shares Fall in Nasdaq Debut - marketscreener.com
Merck veteran Perlmutter-led Eikon Therapeutics valued at $860 million in Nasdaq debut - Yahoo Finance
Eikon IPO grows to biggest for biotech since 2024, raising nearly $400 million before stock falls in debut - The Business Journals
Eikon Therapeutics Opens At $17.05, IPO Priced At $18 By Investing.com - Investing.com Canada
Eikon’s $381M raise represents largest biopharma IPO in two years - BioWorld MedTech
Eikon Therapeutics, Inc. Rings the Opening Bell - Nasdaq
Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO - 1470 & 100.3 WMBD
Eikon Therapeutics raises $381M in IPO - Axios
Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings - BioPharma Dive
Eikon Therapeutics prices upsized IPO at $18 per share By Investing.com - Investing.com Nigeria
Merck Veteran-Led Eikon Therapeutics Raises $381 Million in IPO - bloomberg.com
Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering - Chartmill
Preview: Eikon Therapeutics, Inc Set To IPO Tomorrow - Benzinga
Eikon Therapeutics IPO: Pipeline, Technology Platform, Key Collaborations & Investment Highlights for 2026 - Minichart
Eikon aims high for NASDAQ listing: Public Equity Report - BioCentury
IPO Rating: Eikon Therapeutics, Inc. - Smartkarma
Eikon Therapeutics seeks up to $317M raise in Nasdaq IPO - BioWorld MedTech
Market Chatter: Merck Expected to Take $30 Million Stake in Eikon Therapeutics' IPO - 富途牛牛
Merck veteran-led Eikon seeks $908M valuation in US IPO - MSN
Merck (MRK) Invests in Eikon Therapeutics' IPO - GuruFocus
Merck veteran Perlmutter-led Eikon Therapeutics eyes $908 million valuation in IPO - MSN
Merck veteran Perlmutter-led Eikon ?Therapeutics eyes $908 million valuation in IPO - marketscreener.com
Eikon Therapeutics targets $317M raise in IPO - Axios
Eikon Therapeutics Eyes $908M Valuation in U.S. IPO Under Roger Perlmutter's Leadership - StockInvest.us
Merck to Acquire $30M Stake in Eikon Therapeutics - intellectia.ai
Eikon Therapeutics Launches IPO For Ambitious Oncology Pipeline Development (Pending:EIKN) - Seeking Alpha
IPOs, whale-sized fundings and an animal testing debate ahead of biotech's big JPM conference - The Business Journals
Eikon, a high-profile startup led by Merck vets, seeks an IPO - BioPharma Dive
Phase 2 biotech developing in-licensed therapies for immuno-responsive cancers. - renaissancecapital.com
Eikon Therapeutics Announces the Election of David W. Meline to its Board of Directors - Business Wire
Eikon Therapeutics to Present New Phase 2 Data on EIK1001 in First-Line Non-Small Cell Lung Cancer at ESMO 2025 - Business Wire
Eikon Therapeutics to Share Clinical Data and Program Updates at the 2025 ASCO Annual Meeting - Business Wire
Bay Area biotech company cuts 55 jobs, blames Trump-era funding reductions - San Francisco Chronicle
Well-funded biotech company lays off 55 in Bay Area, blames Trump admin - SFGATE
Eikon Therapeutics just raised $351 million — now it's cutting jobs thanks to Trump rollbacks - The Business Journals
In Vivo’s 2025 Rising Leaders - Citeline News & Insights
Eikon Therapeutics describes new WRN inhibitors - BioWorld MedTech
Biotech Startup Eikon Therapeutics Locks Up Massive $351M Series D - Crunchbase News
Eikon Takes TLR7/8 Agonist Into Phase III With Latest VC Mega-Round - Citeline News & Insights
Eikon Therapeutics Announces Nature Methods Publication Highlighting its Pioneering Oblique Line Scan Technology - BioSpace
Eikon Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Eikon Therapeutics Appoints COO: People in the News: 11/27/24 | Business | Nov 2024 - Photonics Spectra
Eikon Therapeutics Announces Appointment of Michael Klobuchar as Chief Operating Officer - Business Wire
Eikon Therapeutics Inc (EIKN) 財務データ
Eikon Therapeutics Inc (EIKN) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.10%
7.16%
大文字化:
|
ボリューム (24 時間):